Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
J&J wants to appoint lawyer Randi Ellis, who helped it prepare for its third talc-related chapter 11 filing, but the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback